Cancers (Jun 2022)
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid Leukemia
- David Martínez-Cuadrón,
- Josefina Serrano,
- José Mariz,
- Cristina Gil,
- Mar Tormo,
- Pilar Martínez-Sánchez,
- Eduardo Rodríguez-Arbolí,
- Raimundo García-Boyero,
- Carlos Rodríguez-Medina,
- Carmen Martínez-Chamorro,
- Marta Polo,
- Juan Bergua,
- Eliana Aguiar,
- María L. Amigo,
- Pilar Herrera,
- Juan M. Alonso-Domínguez,
- Teresa Bernal,
- Ana Espadana,
- María J. Sayas,
- Lorenzo Algarra,
- María B. Vidriales,
- Graça Vasconcelos,
- Susana Vives,
- Manuel M. Pérez-Encinas,
- Aurelio López,
- Víctor Noriega,
- María García-Fortes,
- María C. Chillón,
- Juan I. Rodríguez-Gutiérrez,
- María J. Calasanz,
- Jorge Labrador,
- Juan A. López,
- Blanca Boluda,
- Rebeca Rodríguez-Veiga,
- Joaquín Martínez-López,
- Eva Barragán,
- Miguel A. Sanz,
- Pau Montesinos,
- on behalf of the PETHEMA Group
Affiliations
- David Martínez-Cuadrón
- Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Josefina Serrano
- Hospital Universitario Reina Sofía and Instituto Maimónides de Investigación Biomédica Córdoba (IMIBIC), 14004 Córdoba, Spain
- José Mariz
- IPO (Istituto Portugues Oncologia), 4200-072 Porto, Portugal
- Cristina Gil
- Hospital General Universitario de Alicante, 03010 Alicante, Spain
- Mar Tormo
- Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
- Pilar Martínez-Sánchez
- Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, 28041 Madrid, Spain
- Eduardo Rodríguez-Arbolí
- Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain
- Raimundo García-Boyero
- Hospital General Universitari de Castelló, 12004 Castellón, Spain
- Carlos Rodríguez-Medina
- Hospital Universitario de Gran Canaria Doctor Negrín, 35010 Las Palmas, Spain
- Carmen Martínez-Chamorro
- Hospital Quirón Pozuelo, 28223 Madrid, Spain
- Marta Polo
- Hospital Clínico San Carlos, 28040 Madrid, Spain
- Juan Bergua
- Hospital San Pedro Alcántara, 10003 Cáceres, Spain
- Eliana Aguiar
- Hospital Sao Joao, 4200-319 Porto, Portugal
- María L. Amigo
- Hospital General Universitario Morales Meseguer, 30008 Murcia, Spain
- Pilar Herrera
- Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain
- Juan M. Alonso-Domínguez
- Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain
- Teresa Bernal
- Hospital Universitario Central de Asturias, 33011 Asturias, Spain
- Ana Espadana
- Hospital de Coimbra, 3400-091 Coimbra, Portugal
- María J. Sayas
- Hospital Universitario Doctor Peset, 46017 Valencia, Spain
- Lorenzo Algarra
- Hospital General Universitario de Albacete, 02006 Albacete, Spain
- María B. Vidriales
- Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), 37007 Salamanca, Spain
- Graça Vasconcelos
- Hospital de Santa Maria, 1649-028 Lisboa, Portugal
- Susana Vives
- ICO-Hospital Germans Trias i Pujol, Badalona, José Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain
- Manuel M. Pérez-Encinas
- Hospital Clínico Universitario de Santiago-CHUS, 15706 Santiago de Compostela, Spain
- Aurelio López
- Hospital Arnau de Vilanova, 46015 Valencia, Spain
- Víctor Noriega
- Complejo Hospitalario Universitario A Coruña, 15006 La Coruna, Spain
- María García-Fortes
- Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain
- María C. Chillón
- Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), 37007 Salamanca, Spain
- Juan I. Rodríguez-Gutiérrez
- Hospital Universitario de Basurto, 48013 Bilbao, Spain
- María J. Calasanz
- Clínica Universidad de Navarra, 31008 Pamplona, Spain
- Jorge Labrador
- Hospital Universitario de Burgos, 09006 Burgos, Spain
- Juan A. López
- Complejo Hospitalario Ciudad de Jaén, 23007 Jaén, Spain
- Blanca Boluda
- Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Rebeca Rodríguez-Veiga
- Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Joaquín Martínez-López
- Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, 28041 Madrid, Spain
- Eva Barragán
- Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Miguel A. Sanz
- Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Pau Montesinos
- Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- on behalf of the PETHEMA Group
- DOI
- https://doi.org/10.3390/cancers14112817
- Journal volume & issue
-
Vol. 14,
no. 11
p. 2817
Abstract
This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p p FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.
Keywords
- acute myeloid leukemia
- <i>FLT3</i>-ITD mutation
- real-world outcomes
- relapsed/refractory disease
- salvage therapy